# A 4-Week Study of the Safety, Efficacy, and Pharmacokinetics of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate Hydrochloride] in Subjects With Parkinson's Disease and Excessive Sleepiness

> **NCT03037203** · PHASE2 · COMPLETED · sponsor: **Jazz Pharmaceuticals** · enrollment: 66 (actual)

## Conditions studied

- Excessive Sleepiness
- Parkinson Disease

## Interventions

- **DRUG:** JZP-110
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03037203
- **Lead sponsor:** Jazz Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01
- **Primary completion:** 2018-08
- **Final completion:** 2018-08
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2020-01-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03037203

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03037203, "A 4-Week Study of the Safety, Efficacy, and Pharmacokinetics of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate Hydrochloride] in Subjects With Parkinson's Disease and Excessive Sleepiness". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03037203. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*